



Prof. Dr Jürgen Eckel
Chief Executive Officer & Founder

Professor at the German Diabetes Center; 40+ years of experience with patents and 200+ publications.



STOP-MASH

CMR
CureDiab
Metabolic Research GmbH

Novel first-in-class drug
targeting metabolic liver disease



Company **Overview**

CureDiab: Leading Innovation in Liver Health and Fibrosis Therapies

Who We Are

Spin-off from the German Diabetes Center.

What We Do

First-in-class drug (HK3) for MASLD/ MASH (fatty liver disease).

How We Do It

Preclinical data with expert knowledge.

Why We Do It

€126B global need to transform patient care.

Medical Problem

MASLD/MASH:

A Global Health Crisis Driven by Lifestyle and Biological Factors

Factors:



Lifestyle Factors

Poor nutrition and physical inactivity.



Biological Factors

Genetics, microbiome imbalances.



Results:



MASLD

Liver disease with fat accumulation and insulin resistance as primary drivers.



MASH

A severe form of MASLD with liver inflammation and cell damage.



Obesity

A condition of excessive fat accumulation that presents a risk to health.



Diabetes


A chronic disease, causing high blood sugar due to insufficient or ineffective insulin.

Our Solution

HK3 - A Multi-Targeted Drug

Introducing HK3

A non-brain penetrating, first in class, allosteric modulator of the GABA-A receptor, targeting the challenges of MASLD/MASH.



Key Benefits:


Liver protection

Reduces **fat buildup**, **inflammation**, and **cell death** in liver cells (hepatocytes).



Fibrosis Reversal

Decreases liver **scarring** in hepatic stellate cells.



Weight effects

Lowers **body weight** and **fat mass** while preserving lean mass.






Safe and Precise

No impact on the **central nervous system**.



AI-based approach to identify anti-fibrotic compounds



Collaboration with molab.ai

Outlook

We offer substantial expertise in metabolic research with state-of-the-art lab equipment including a recently funded Eurostars project using organ-on-chip technology

We have novel anti-fibrotic molecules and look for med-chem and drug development groups to establish or participate in a consortium addressing EU funded research in the field of fibrosis (liver, kidney, lung)



www.curediab.de

juergen.eckel@curediab.de